Start-up to increase Supercomputing Access through Partnerships
The injection of joint funding will support UnitX in its quest to democratise supercomputing and help enterprises of
all sizes
leverage technologies such as high performance data analytics to make data-driven decisions, reduce IT spending, innovate and become globally competitive through partnership structures.
Tamer Osman, head of the KAUST Innovation Fund, stated: “UnitX is bridging a new frontier in advancing big compute power and making it more accessible to sectors that have previously been unable to access the benefi ts of supercomputing. At KAUST, we are actively investing in startups and technology that are shaping industry 4.0, and UnitX is a deep tech startup at the forefront of this revolution.”
Pictured from left: Dr Ravi Samtaney, UnitX co-founder, KAUST professor and acting dean of the University’s Physical Science and Engineering Division; Mohammed Ghawanni, UnitX product engineer; Kiran Narayanan, UnitX co-founder and CEO; and Ankita Shree, UnitX co-founder. Credit: Ryan Yangyang, UnitX
Artifi cial intelligence (AI) and supercomputing start-up UnitX a spin- out of KAUST has secured $2 million of co-investment from the KAUST Innovation Fund and Saudi Aramco’s Wa’ed Ventures Fund.
Salman T. Jaffrey, Chief Investment Offi cer at Wa’ed Ventures and an incoming board member on UnitX, praised the efforts and ambition of UnitX’s cofounders - Kiran Narayanan, Ravi Samtaney, Ankita Shree and Salman Kattan - and their inspiring journey.
“We are thrilled to have led this investment with KAUST, which is testament to our fund’s inimitable approach on fueling the growth of Kingdom-based startups and shared vision of advancing the Saudi venture ecosystem,” Mr Jaffrey said.
51130pr@reply-direct.com
Phil Jones Research undertaken as part
EU Project Identifies Potential New
Treatments for Cancer
of
the European Lead Factory
Project, brought together scientists from the German Cancer Research Center (DKFZ), the Pivot Park Screening Centre and BioAscent in the discovery of potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.
PREP-2020 Preparative & Process Chromatography Conference Announced
SFC, fi ne chemicals, peptides, proteins, oligonucleotides, APIs, natural
products, batch, multi-column and continuous SMB
processes, column technology and equipment, monoliths, new and improved stationary phases, membrane chromatography, product quality, stability, safety and/or immunogenicity and related process control strategies, regulatory aspects and more.
PREP-2020, the 33rd International Symposium on Preparative & Process Chromatography Conference, to be held at the Hyatt Regency Hotel in Baltimore, USA, from 31 May - 3 June, will be showcasing the latest scientifi c advances. The programme is packed with papers on biochromatography, downstream processing, QbD, monoclonal antibodies, plasmids, enzymes, vaccines, viral vectors for gene delivery, VLPs and other biopharmaceuticals, clearance of high-risk impurities such as host cell proteins, chiral molecules,
Join in for four days of exciting science, technology and education at PREP-2020, the longest running, highly recognised international conference and exposition driving the fi eld of preparative and process chromatography. World renowned speakers will address in-depth the latest scientifi c and technological advances, critical and emerging applications and processes, and challenges and solutions in all aspects of Preparative and Process Chromatography, Ion Exchange, Adsorption/Desorption Processes and Related Separation Techniques.
More information online:
ilmt.co/PL/n0Zr 50966pr@reply-direct.com
The collaborative group proposed a study of Kallikrein-related peptidase 6 (KLK6) in the development, invasiveness and metastasis of some cancers, including colon cancer and melanomas.
Initial high throughput screening performed at the Pivot Park Screening Centre identifi ed a cluster of initial hits that showed consistent inhibitory activity against KLK6; these were improved on using multi-step synthesis procedures to produce novel chiral compounds that were tested using a range of biophysical and biochemical assays. The team of biologists and chemist scientists has since transitioned to BioAscent.
Dr Phil Jones, Chief Scientifi c Offi cer at BioAscent, said: “Historically the infrastructure and expertise to carry out this type of approach has only really been available in major pharma companies. BioAscent now has the facilities and breadth of expertise and experience to perform these studies and provide our clients with excellent opportunities to advance their drug discovery projects.”
Dr Aubry Miller, Cancer Drug Discovery/Wirkstoffforschung Group Leader, DKFZ, was enthusiastic about the collaboration, commenting: “More importantly, the scientists (now at BioAscent) who were involved in the hit development stage, were fully committed to the success of the project, bringing their own ideas and solutions, which made my role as project owner very comfortable. I would be very happy to work with them again.”
51122pr@reply-direct.com
Appointment Progresses Company towards Global Goals Stefan Fraenkel has been appointed CEO at pharmaceutical and service partner company Inceptua effective since 1st January.
Stefan has been leading the creation of one of the company’s three business units, Inceptua Pharma, since 2017. “I’m both humbled and proud to get this opportunity as we are growing and transforming Inceptua to further strengthen our position. I look forward to working closely with all parts of our business and competent teams to further develop Inceptua and help realise our ambition to be a global partner of choice for providing critical treatments to patients in need.”
Chairman of the Board, Peter Krantz, said: “Stefan is an accomplished executive with a strong industry background focusing on commercial deal making, global marketing and sales, and corporate development. I look forward to continue the collaboration with Stefan in his new role as CEO as we take Inceptua to the next level.”
With an MBA and a PhD in international economics, Stefan joined the company in 2017 from Swedish Orphan Biovitrum AB (publ) (Sobi™) where he was Head of Corporate Development. He has also held various international commercial leadership positions in Europe and in the USA, while working at Wyeth/Pfi zer.
The company also confi rmed that Alan Raffensperger had joined the Board of Directors as Executive Vice-Chairman: “As we are growing our company there is a need to further formalise our Board structure. As such we are delighted to announce that Alan Raffensperger will join the Inceptua Board of Directors. During his tenure as CEO, Alan has successfully led Inceptua to where we are today – strongly positioned as a pharmaceutical company and leading service partner spanning throughout the product lifecycle. Over the past two years we have diversifi ed our clinical trial services business, accelerated our early access program portfolio, and fi rmly established Inceptua Pharma. Alan will continue to play an active role in support of our business,” added Peter Krantz.
51131pr@reply-direct.com
Alan Raffensperger
Stefan Fraenkel
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
